TELA Bio, Inc. ( TELA ) NASDAQ Global Market

Cena: 1.78 ( 3.49% )

Aktualizacja 08-22 21:57
NASDAQ Global Market
Branża: Medical - Devices
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Tela Bio, Inc., firma zajmująca się technologią medyczną, koncentruje się na zapewnieniu roztworów rekonstrukcji tkanek miękkich, które optymalizują wyniki kliniczne poprzez priorytetowe traktowanie zachowania i przywrócenia anatomii pacjenta. Zapewnia portfolio produktów tkanek wzmocnionej Ovitex (Ovitex) do naprawy przepukliny i rekonstrukcji ściany brzusznej; oraz produkty tkanek wzmocnionych Owitex PR, aby zaspokoić niezaspokojone potrzeby w chirurgii plastycznej i rekonstrukcyjnej, a także Owitex w przypadku zabiegów laparoskopowych i robotycznych w laparoskopowej i robotycznej macierzy leżącej pochodzi z żwacza jajowskiego z polipropylenowym włóknem. Firma sprzedaje swoje produkty za pośrednictwem jednej bezpośredniej siły sprzedaży, głównie w Stanach Zjednoczonych. Tela Bio, Inc. została zarejestrowana w 2012 roku i ma siedzibę w Malvern w Pensylwanii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 227
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 69.49
Ilość akcji: Brak danych
Debiut giełdowy: 2019-11-08
WWW: https://www.telabio.com
CEO: Mr. Antony Koblish
Adres: 1 Great Valley Parkway
Siedziba: 19355 Malvern
ISIN: US8723811084
Wskaźniki finansowe
Kapitalizacja (USD) 70 517 192
Aktywa: 53 016 000
Cena: 1.78
Wskaźnik Altman Z-Score: -8.4
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.7
Ilość akcji w obrocie: 69%
Średni wolumen: 109 395
Ilość akcji 39 616 400
Wskaźniki finansowe
Przychody TTM 68 649 000
Zobowiązania: 59 288 000
Przedział 52 tyg.: 0.865 - 3.26
Piotroski F-Score: 1
Słaby (niska jakość finansowa)
EPS: -1.1
P/E branży: 29.9
Beta: 0.968
Raport okresowy: 2025-11-06
WWW: https://www.telabio.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Roberto E. Cuca J.D. Chief Financial Officer & Chief Operating Officer 674 777 1968
Mr. Paul Talmo Chief Technology Officer 595 667 1972
Mr. Peter C. Murphy Chief Commercial Officer 542 339 1973
Mr. Antony Koblish Co-founder, President, Chief Executive Officer & Director 1 031 524 1966
Ms. Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer 0 1976
Mr. D. Taylor Ocasio General Counsel & Corporate Secretary 0 0
Mr. Gregory A. Firestone Chief Commercial Officer 0 1959
Louisa Smith Investor Relations Contact Officer 0 0
Ms. Jennifer Lou Armstrong Senior Vice President of Human Resources 0 1970
Mr. Michael Leonard Senior Vice President of Technical Operations 0 0
Lista ETF z ekspozycją na akcje TELA Bio, Inc.
Symbol ETF Ilość akcji Wartość
IWC 82 375 140 036
Wiadomości dla TELA Bio, Inc.
Tytuł Treść Źródło Aktualizacja Link
TELA Bio, Inc. (TELA) Q1 2025 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Louisa Smith - The Gilmartin Group Antony Koblish - Co-founder, President & Chief Executive Office Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon ladies and gentlemen and welcome to the TELA Bio First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. seekingalpha.com 2025-05-11 19:30:34 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 6,600 shares of its common stock to twelve newly-hired employees, with a grant date of May 5, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2025-05-09 20:05:00 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.23 per share a year ago. zacks.com 2025-05-08 22:50:39 Czytaj oryginał (ang.)
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com 2025-04-17 20:05:00 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Q4 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ET Company Participants Greg Chodaczek - The Gilmartin Group Antony Koblish - Co-founder, President and Chief Executive Office Roberto Cuca - Chief Operating Officer and Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity David Turkaly - Citizens Matt O'Brien - Piper Sandler Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-03-21 00:04:58 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.53 per share a year ago. zacks.com 2025-03-20 21:51:05 Czytaj oryginał (ang.)
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. globenewswire.com 2025-03-20 18:05:00 Czytaj oryginał (ang.)
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com 2025-02-27 18:05:00 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2025-01-24 18:05:00 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2024-12-13 18:05:00 Czytaj oryginał (ang.)
TELA Bio to Participate in Piper Sandler's 36th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference. globenewswire.com 2024-11-19 18:05:00 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Q3 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President, Gilmartin Group Tony Koblish - President & Chief Executive Officer Roberto Cuca - Chief Operating Officer & Chief Financial Officer Conference Call Participants Caitlin Cronin - Canaccord Genuity Frank Takkinen - Lake Street Capital Markets Michael Sarcone - Jefferies Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-11-09 15:49:35 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.45 per share a year ago. zacks.com 2024-11-07 21:20:27 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2024-11-01 18:05:00 Czytaj oryginał (ang.)
TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the closing of its previously announced underwritten public offering of 14,670,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, for gross proceeds of $46 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. All shares of common stock and pre-funded warrants were sold by TELA. globenewswire.com 2024-10-24 20:05:00 Czytaj oryginał (ang.)
TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 5,800,000 shares of common stock at a public offering price of $2.2499 per pre-funded warrant, which represents the per share public offering price for the shares of common stock less the $0.0001 per share exercise price for each pre-funded warrant, collectively, for gross proceeds of $40 million, before deducting underwriting discounts and commissions and other estimated offering expenses and assuming no exercise of the pre-funded warrants. In addition, TELA has granted the underwriters a 30-day option to purchase up to an additional 2,670,000 shares of its common stock at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The offering is expected to close on or about October 24, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com 2024-10-23 12:07:00 Czytaj oryginał (ang.)
TELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of its common stock. In addition, TELA expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price for the common stock, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants are being offered by TELA. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering. globenewswire.com 2024-10-22 20:05:00 Czytaj oryginał (ang.)
TELA Bio to Announce Third Quarter 2024 Financial Results MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com 2024-10-17 20:05:00 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Q2 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Matthew O'Brien - Piper Sandler Michael Sarcone - Jefferies David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. seekingalpha.com 2024-08-13 00:37:05 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago. zacks.com 2024-08-12 22:21:04 Czytaj oryginał (ang.)
TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. globenewswire.com 2024-08-12 20:05:00 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 16,000 shares of its common stock to nine newly-hired employees, with a grant date of August 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2024-08-09 20:05:00 Czytaj oryginał (ang.)
TELA Bio to Announce Second Quarter 2024 Financial Results MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Monday, August 12, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com 2024-07-22 20:05:00 Czytaj oryginał (ang.)
TELA Bio Appoints Jeffrey Blizard to its Board of Directors MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. globenewswire.com 2024-06-04 20:05:00 Czytaj oryginał (ang.)
TELA Bio Appoints Greg Firestone as Chief Commercial Officer MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. globenewswire.com 2024-05-20 20:03:00 Czytaj oryginał (ang.)
TELA Bio, Inc. (TELA) Q1 2024 Earnings Call Transcript TELA Bio, Inc. (NASDAQ:TELA ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Louisa Smith - Vice President of Gilmartin Group Antony Koblish - Co-founder, President & CEO Roberto Cuca - COO & CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Caitlin Cronin - Canaccord Genuity Michael Sarcone - Jefferies Matthew O'Brien - Piper Sandler David Turkaly - Citizens JMP Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-05-11 18:35:29 Czytaj oryginał (ang.)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio. globenewswire.com 2024-05-10 20:05:00 Czytaj oryginał (ang.)
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. globenewswire.com 2024-05-09 20:05:00 Czytaj oryginał (ang.)
TELA Bio to Announce First Quarter 2024 Financial Results MALVERN, Pa., April 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2024 financial results on Thursday, May 9, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. globenewswire.com 2024-04-25 11:00:00 Czytaj oryginał (ang.)